{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:33:59Z","timestamp":1775280839412,"version":"3.50.1"},"reference-count":30,"publisher":"The Japanese Society of Nuclear Cardiology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,31]]},"DOI":"10.17996\/anc.21-00139","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T22:09:47Z","timestamp":1623362987000},"page":"33-42","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Add-on Therapy with Carvedilol and the Direct Renin Inhibitor Aliskiren for Improving Cardiac Sympathetic Nerve Activity, Cardiac Function, Symptoms, Exercise Capacity and Brain Natriuretic Peptide in Patients with Dilated Cardiomyopathy"],"prefix":"10.17996","volume":"7","author":[{"given":"Takuji","family":"Toyama","sequence":"first","affiliation":[{"name":"Division of Cardiology, Toyama Cardiovascular Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Kasama","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nara Medical University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Miyaishi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakuken","family":"Kan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Adachi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hoshizaki","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Gunma Prefectural Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7364","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978; 41: 233–43.","DOI":"10.1016\/0002-9149(78)90162-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022–36.","DOI":"10.1136\/hrt.37.10.1022"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; 1: 1374–6.","DOI":"10.1016\/S0140-6736(79)92010-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9–13.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. MERIT-HF Study Group. Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/Xl randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001–7.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N Engl J Med 1996; 334: 1349–55.","DOI":"10.1056\/NEJM199605233342101"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651–8.","DOI":"10.1056\/NEJM200105313442201"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449–56.","DOI":"10.1016\/S0140-6736(06)69442-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. McMurray JJV, Pfeffer MA, Swedberg K, Dzau VJ. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation 2004; 110: 3281–8.","DOI":"10.1161\/01.CIR.0000147274.83071.68"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12: 1252–8.","DOI":"10.1016\/0735-1097(88)92608-3"},{"key":"11","unstructured":"11. Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33: 471–7."},{"key":"12","unstructured":"12. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995; 36: 2138–47."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Inoko M, Fujita M, Nakae I, Tamaki S, Watanuki M, Hashimoto T, et al. Effect of angiotensin-converting enzyme inhibition on sympathetic tone in patients with mild to moderate heart failure. Jpn Circ J 2001; 65: 395–8.","DOI":"10.1253\/jcj.65.395"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Adachi H, Itoh H, Sakurai S, Takahashi T, Toyama T, Naito S, et al. Short-term physical training improves ventilatory response to exercise after coronary arterial bypass surgery. Jpn Circ J 2001; 65: 419–23.","DOI":"10.1253\/jcj.65.419"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. McMurray JJV, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17–24.","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Alderman J, Grossman W. Are beta-adrenergic-blocking drugs useful in the treatment of dilated cardiomyopathy? Circulation 1985; 71: 854–7.","DOI":"10.1161\/01.CIR.71.5.854"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84: 2426–41.","DOI":"10.1161\/01.CIR.84.6.2426"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, et al. Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J Am Coll Cardiol 1993; 21: 628–33.","DOI":"10.1016\/0735-1097(93)90094-H"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993; 87: 454–63.","DOI":"10.1161\/01.CIR.87.2.454"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994; 24: 1310–20.","DOI":"10.1016\/0735-1097(94)90114-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Maisel AS. Beneficial effects of metoprolol treatment in congestive heart failure. Reversal of sympathetic-induced alterations of immunologic function. Circulation 1994; 90: 1774–80.","DOI":"10.1161\/01.CIR.90.4.1774"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sanderson JE, Chan SK, Yip G, Yeung LY, Chan KW, Raymond K, et al. Beta-blockade in heart failure: A comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999; 34: 1522–8.","DOI":"10.1016\/S0735-1097(99)00367-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99: 2645–51.","DOI":"10.1161\/01.CIR.99.20.2645"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Cas LD. Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000; 102: 546–51.","DOI":"10.1161\/01.CIR.102.5.546"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94: 2817–25.","DOI":"10.1161\/01.CIR.94.11.2817"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1–8.","DOI":"10.1161\/hy0102.102293"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003; 308: 698–705.","DOI":"10.1016\/S0006-291X(03)01451-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, et al; Val-HeFT Investigators. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 2006; 119: 70.e23–e30.","DOI":"10.1016\/j.amjmed.2005.08.041"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49: 1733–9.","DOI":"10.1016\/j.jacc.2006.10.081"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R; Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: Results from the Valsartan Heart Failure Trial. Circulation 2003; 108: 1306–9.","DOI":"10.1161\/01.CIR.0000091234.45664.62"}],"container-title":["Annals of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/anc\/7\/1\/7_21-00139\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T03:49:01Z","timestamp":1630727341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/anc\/7\/1\/7_21-00139\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.17996\/anc.21-00139","relation":{},"ISSN":["2189-3926","2424-1741"],"issn-type":[{"value":"2189-3926","type":"print"},{"value":"2424-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"article-number":"21-00139"}}